Clinigen Share Discussion Threads

[nermil] 01/8/2013 14:42

Nurdin how do you calculate that peg what growth rate is that based on? Been watching for a while. Damn thing gets tipped. Seems I dithered too long now looks a bit peaky to me. But a peg of .4 still is attractive if its a good est.

[plasybryn] 31/7/2013 17:02

Did the market miss this RNS today?

Seems so with a fall in the S.P.

Not sure how much it is worth though.

[sparkymoc] 30/7/2013 20:02

Have been wanting to buy this the last few days but the spread is huge.

Is it normally so big?

[sparkymoc] 30/7/2013 20:00

droid, there already is one

[oilplays] 30/7/2013 11:49

Thanks droid I'm thinking of buying for ISA when aim stocks permitted but hope not too late. Cazenove still hold.

[droid] 30/7/2013 11:01

Amazed there was no thread for this one and equally amazed how easy it was to start one.

[sparkymoc] 27/7/2013 10:58

Cheers.

Was hoping for the GAP to be a bigger percentage.

Is it worrisome that sales in CTS can be 'lumpy'?

[peladon] 27/7/2013 08:52

Sparky

These figures were given by SCSW in November 2012:

• global access programs (2% of sales);

• sale of owned drugs (26%);

• clinical trial supply (72%)

[sparkymoc] 27/7/2013 08:15

Hi nudin

How are you coming up with a pe of 14? I make it more than that?

Also, anyone know what the split is between the 3 sections CTS, GAP and share price in terms of revenue/profits?

Cheers

[ceohunter] 26/7/2013 11:10

video interview
Clinigen targets more products to boost drive for growth

Peter George, CEO of Clinigen Group (LON:CLIN), tells Proactiveinvestors that all parts of the business are contributing to growth. The target, Peter says, is to be the world's number one in Clinical Trials Supply (CTS) and Global Access Programs (GAP). The strategy remains in place to drive growth across all parts of the company. To this end Clinigen has put in place changes to the board structure to help achieve the targets set.

[ygor706] 25/7/2013 19:17

Thinks there is lots more to come here ....... trend os firmly upwards.

[nurdin] 25/7/2013 10:36

Still trading on current year PE of just 14x with a peg of 0.4....and that's without the benefit of any new acquisitions. I don't know if the brokers estimates allow for any contribution from CLINs more recent acquisitions but I suspect that,if they have, then these will be on a conservative side.

A lot to look forward to imo.

[cestnous] 25/7/2013 08:16

Yes, nice rise with it as well.

[peladon] 25/7/2013 08:15

Good upbeat statement. "Ahead of expectations" :-)

[nurdin] 15/7/2013 14:21

yup...nice to see ;o)

[cestnous] 15/7/2013 14:12

It's kicked in now Nurdin. :¬)

[nurdin] 15/7/2013 08:51

Hmmm....not much of a reaction to the DM tip.....but then the day is young...:o)

[the oak tree] 13/7/2013 12:37

I remember seeing them as well in SCSW and was very tempted at the time. Didn't buy them though, so well done to those that did - a great business.

[peladon] 13/7/2013 12:06

:-( I'm only up 49%

[cornishman33] 13/7/2013 11:47

Yes thanks for that Nurdin. A positive report which will do no harm, and bring CLIN to a wider audience. I bought a small holding last November after SCSW put them in their portfolio and I am now up over 50%. Yesterday they reached an ATH.

[peladon] 13/7/2013 11:04

Thanks Nurdin

[nurdin] 13/7/2013 10:56

Nice tip in the Daily Mail today...half a page spread. Hoping for fireworks on Monday...;o)

[ceohunter] 09/7/2013 08:35

video interview
Clinigen reveals AIM success story is primed for further growth

Clinigen (LON:CLIN) was unique for an AIM float. When it came to the market last September it was not only the first pharmaceutical IPO in almost five years, but it was profitable and cash generative. It is also now a dividend payer. Chief executive officer Peter George and chief financial officer Robin Sibson reveal how this drug sector hybrid will continue on its exponential growth trajectory.